ESTRO 2024 - Abstract Book

S1624

Clinical - Lung

ESTRO 2024

Chemotherapy concurrent

9 (15%)

Chemotherapy sequential

15 (25%)

Median PTV (cc)

106 cc (46-222)

After a median follow-up of 26.5 months (IQR 15.9 – 30.7 months), median OS was 30.1 months (IQR 20.5 – 39.7). The 2-year OS rate was 56% (95% CI 43.0%-71.9%, Figure 1). The 2-year OS rate was 62%, 53% and 52% for SBRT, radiotherapy alone and chemoradiotherapy, respectively (p=0.845). Twenty-five patients had a local failure, Median LC was 28.2 months (95% CI 14.3 – not reached) with a 2 year LC rate of 53% (95% CI 39.5%-69.9%, Figure 2). Median DFS was 13.6 months (95% CI 8.4-19.7). The 2-year DFS rate was 28% (95% CI 17.9-43.7).

Figure 1 – Overall survival for all patients

The dashed lines are showing the 95% confidence interval

Figure 2 – Local control for all patients